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Background: Dyspnea and a reduced exercise capacity is often experience by patients with hypertrophic cardiomyopathy (HCM) and 
correlate with echocardiographic signs of diastolic dysfunction and left ventricular outflow tract obstruction. The association between left 
ventricle dimensions and function assessed by cardiac magnetic resonance imaging (CMR) or cardiac computed tomography (CT) and 
exercise capacity in HCM has not been previously assessed.
methods: We examined 133 adult patients with HCM (52 ±13 years, 35% female) with a symptom-limited exercise test, echocardiography 
and CMR or CT (patients with ICD).
results: Estimated peak VO2 was 26±10 ml/O2/min. Twenty-eight percent (13/47) of women and 24% (21/86) of men reached their 
predicted peak VO2. In the multiple regression analysis left ventricular end-diastolic diameter (LVEDd), E/ e’, age and sex emerged as 
independent predictors of peak VO2 (Table 1). According to the model 10 ml/m2 increase in left ventricular end-diastolic diameter was 
accompanied by an increase in VO2 of 1.25±0.61 ml/O2/min (p<0.05).
conclusion:  We found end-diastolic volume to be an important predictor of exercise capacity. In accordance with previous findings we 
also found diastolic dysfunction to be associated with a low exercise capacity. The CMR/CT finding of a small left ventricular cavity as a 
contributor to exercise intolerance in HCM is novel and implicates further exploration of left ventricular size as a limiting factor and as a 
possible treatment target in HCM.
Table. Univariate and multivariable linear regression of estimated VO2
Univariate Multivariate Univariate Multivariate
Variable β, (95% CI), p β, (95% CI), p Variable β, (95% CI), p β, (95% CI,) p
Age (per 10 years increase)
-3.28, (-4.43 - -2.13), 
p<0.0001
-1.87, (-3.37- 
-0.37), p<0.05
Late gadolinium enhancement (per 
absolute 10 % increase)
0.23, (-0.13-0.26), 
p=0.20
Female sex
-7.10, (-10.37- -3.82), 
p<0.0001
-5.44, (-9.11- - 
1.77), p<0.01
LA volume (per 10 ml/m2 increase)
-0.13, (-1.10-0.84), 
p=0.79
Betablocker or calcium 
antagonist
-3.23, (-6.70-0.24), 
p=0.07
LVOT gradient at rest
-0.03, (-0.09-0.04), 
p=0.44
Heart rate at rest (per 10 BPM 
increase)
-0.38, (-1.84-1.08), 
p=0.61
LVOT gradient during Valsalva
-0.05, (-0.10-0.00), 
p=0.05
NS
LV mass (per 10g /m2 increase)
0.48, (0.00-0.96), 
p=0.05
NS E/e’’ ratio (per 10 % increase)
-0.89, (-1.26- -0.51), 
p<0.0001
-0.50, (-0.90- 
-0.10), p<0.05
LV maximal wall thickness
-0.19 (-0.47-0.10), 
p=0.20
Early deceleration time
-0.28, (-0.48- -0.08), 
p<0.01
NS
LV end diastolic volume (per 10 
ml/m2 increase)
2.20, (1.29-3.12), 
p<0.0001
1.25, (0.03-2.47), 
p<0.05
Presence of mitral regurgitation
1.12, (-3.34-4.58), 
p=0.52
Stroke volume (per 10 ml 
increase)
3.44, (1.58-5.31), 
p<0.001
NS Global longitudinal strain
-0.42, (-0.86-0.01), 
p=0.06
Cardiac output (per 100 ml 
increase)
0.14, (0.01-0.26), 
p=0.04
NS
